Get notified of page updates

Featured Research Search Results

PRINTER FRIENDLY PAGE

Search

Virtual
Virtual
PRINTER FRIENDLY PAGE
54 Results Found

Featured research search results for

Treatment

Comparing an Experimental Drug Puxi-Sam with Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)

Clinicaltrials.gov identifier:
NCT07044336

Treatment
Phase 3 treatment study for metastatic endometrial cancer

Phase 3

Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab

Clinicaltrials.gov identifier:
NCT07397338

Treatment
Treatment study for solid tumors with a RAS mutation

Phase 1/2

Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT06841354

Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer

Phase 3

Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors

Clinicaltrials.gov identifier:
NCT06128551

Treatment
Treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation

Phase 1/2

Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors

Clinicaltrials.gov identifier:
NCT06411691

Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation

Phase 1

Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)

Clinicaltrials.gov identifier:
NCT05879926

Treatment
Study for premenopausal, early-stage, ER positive, HER2-negative breast cancer

Phase 3

Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab

Clinicaltrials.gov identifier:
NCT05112601

Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker

Phase 2

Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

Clinicaltrials.gov identifier:
NCT05372640

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Phase 1

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Phase 1

Post-surgery Immunotherapy (Toripalimab) for MMR-D / MSI-H Stage IIB-III Colon Cancer

Clinicaltrials.gov identifier:
NCT07140679

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

Phase 2

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT06958328

Treatment
Radiation treatment study for people with locally advanced pancreatic cancer

Phase 3

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer

Clinicaltrials.gov identifier:
NCT06952803

Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer

Phase 3

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations

Clinicaltrials.gov identifier:
NCT04890613

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Phase 1

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

Phase 3

Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs

Clinicaltrials.gov identifier:
NCT06167317

Treatment
Treatment study for people with advanced or metastatic solid tumors

Phase 1

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib

Clinicaltrials.gov identifier:
NCT06488378

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Phase 1

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT06401421

Treatment
Biomarker study for people with early-stage breast cancer